Speaker Profile
Ph.D., Chief Data Officer, Oxford BioDynamics
Biography
Ewan with 20 years of experience in the biotech industry, spanning technical leadership in statistics, computational biology as well as senior, business-focused roles. He has held positions at several leading organizations, including Silicon Genetics, Agilent Technologies, Thomson Reuters, and Selventa.
He earned his undergraduate degree in Biochemistry from the University of Edinburgh and completed his PhD at King’s College London (formerly Guy’s & St Thomas’ Medical School), where his research focused on the temporal analysis of brain development.
Ewan joined OBD in 2012 and has played a pivotal role in shaping the company’s early biomarker strategy. His work has included the development of statistical data pipelines, feature engineering approaches, and machine learning solutions. More recently, he has led a dedicated team of biological data scientists applying semantic parsing techniques to build a comprehensive knowledge graph that integrates established biological knowledge with OBD’s proprietary 3D genomic data, culminating in the development of EpiSwitch® Orion.
Talk
Unfolding the Genome's "Natural Intelligence” with EpiSwitch Orion
DNA "Natural Intelligence"—a 3D control system that determines when genes turn on or off. EpiSwitch Orion maps this hidden structure, revealing how genetic control is disrupted in disease. By analyzing individual and population data, it turns static DNA into actionable insights for targeted therapies.
AI and Data Sciences Showcase:
Oxford BioDynamics
Oxford BioDynamics Plc (OBD) is a global biotechnology company, advancing personalized healthcare by commercializing precision medicine tests. The Company's product portfolio is based on a proprietary 3D genomic biomarker platform, EpiSwitch®, built for the prediction of response to therapy, patient prognosis and disease diagnosis.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
